Candelaria M, Oñate-Ocaña LF, Corona-Herrera J, Barrera-Carmona C, Ponce-Martínez M, Gutiérrez-Hernández O, Avilés-Salas A, Cacho-Díaz B

Language: English
References: 39
Page: 349-358
PDF size: 181.19 Kb.

ABSTRACT

Background: The outcome of patients with primary extranodal diffuse large B-cell lymphoma (PE-DLBCL) varies according to the primary site involved. Primary gastrointestinal, breast, bone, craniofacial, and testicular DLBCL are rare extranodal manifestations of DLBCL. Objective: The objective of the study was to describe the clinical course of patients with PE-DLBCL disease in a referral cancer center. Results: From 637 patients, 51 (8.77%) were considered as having PE-DLBCL (25 gastrointestinal, 12 craniofacial, 6 breast, 5 bone, and 3 with primary testicular DLBCL). Complete remission was higher in all PE-DLBCL sites (100% in testicular, 92.6% craniofacial, 83.3% breast, 80% bone, and 80% gastrointestinal) compared with 73.3% in nodal DLBCL. Although 2 cases with breast PE-DLBC relapsed, they achieved a complete response with chemotherapy. The overall survival at 5 years was 100%, 80%, 78%, 58%, 58%, and 62% for patients with primary breast, primary bone, gastrointestinal, primary craniofacial, primary testicular, and nodal DLBCL, respectively. Conclusions: PE-DLBCLs constitute rare, primary sites of lymphoproliferative disorders in most cases, with localized disease and good prognosis. They require a combined chemoimmunotherapy with radiotherapy in most cases to improve local and systemic disease.

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.

2. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Diffuse large B-cell lymphoma version 1.2016. J Natl Compr Canc Netw. 2016;14:196-231.

3. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127:2375-90.

4. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella- Branger D, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803-20.

5. Lee DY, Kang K, Jung H, Park YM, Cho JG, Baek SK, et al. Extranodal involvement of diffuse large B-cell lymphoma in the head and neck: an indicator of good prognosis. Auris Nasus Larynx. 2019;46:114-21.

6. Validire P, Capovilla M, Asselain B, Kirova Y, Goudefroye R, Plancher C, et al. Primary breast non-Hodgkin’s lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol. 2009;84:133-9.

7. Mattia AR, Ferry JA, Harris NL. Breast lymphoma. A B-cell spectrum including the low grade B-cell lymphoma of mucosa associated lymphoid tissue. Am J Surg Pathol. 1993;17:574-87.

8. Zhang X, Zhu J, Song Y, Ping L, Zheng W. Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients. Sci Rep. 2016;6:28834.

9. Limb D, Dreghorn C, Murphy JK, Mannion R. Primary lymphoma of bone. Int Orthop. 1994;18:180-3.

10. Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer. 2006;106:2652-6.

11. Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, et al. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2015;92:122-9.

12. Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer. 1990;65:1864-6.

13. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-82.

14. Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer. 1972;29:1705-12.

15. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685-93.

16. Meignan M, Gallamini A, Haioun C, Barrington S, Itti E, Luminari S, et al. Report on the 5th international workshop on positron emission tomography in lymphoma held in Menton, France, 19- 20 September 2014. Leuk Lymphoma. 2015;56:1229-32.

17. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86.

18. Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014;165:358-63.

19. Lalani N, Winkfield KM, Soto DE, Yeap BY, Ng AK, Mauch PM, et al. Management and outcomes of women diagnosed with primary breast lymphoma: a multi-institution experience. Breast Cancer Res Treat. 2018;169:197-202.

20. Zhang N, Cao C, Zhu Y, Liu P, Liu L, Lu K, et al. Primary breast diffuse large B-cell lymphoma in the era of rituximab. Onco Targets Ther. 2016;9:6093-7.

21. Hayase E, Korosawa M, Suzuki H, Kasahara K, Yamakawa T, Yonezumi M. et al. Primary bone lymphoma: a clinical analysis of 17 patients in a single institution. Acta Haematol. 2015; 134:80-85.

22. Lombard M, Michel G, Rives P, Moreau A, Espitalier F, Malard O, et al. Extranodal non-hodgkin lymphoma of the sinonasal cavities: a 22-case report. Eur Ann Otorhinolaryngol Head Neck Dis. 2015;132:271-4.

23. Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the international extranodal lymphoma study group. Ann Oncol. 2008; 19:233-41.

24. Aviles A, Neri N, Nambo MJ. The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast. Am J Clin Oncol. 2012;35:126-9.

25. Shao YB, Sun XF, He YN, Liu CJ, Liu H. Clinicopathological features of thirty patients with primary breast lymphoma and review of the literature. Med Oncol. 2015;32:448.

26. Ganjoo K, Advani R, Mariappan MR, McMillan A, Horning S. Nonhodgkin lymphoma of the breast. Cancer. 2007;110:25-30.

27. Hattori M, Frazier J, Miles HT. Poly(8-aminoguanylic acid): formation of ordered self-structures and interaction with poly (cytidylic acid). Biochemistry. 1975;14:5033-45.

28. Matikas A, Briasoulis A, Tzannou I, Oikonomopoulou D, Bakiri M, Karmiris T, et al. Primary bone lymphoma: a retrospective analysis of 22 patients treated in a single tertiary center. Acta Haematol. 2013;130:291-6.

29. Horsman JM, Thomas J, Hough R, Hancock BW. Primary bone lymphoma: a retrospective analysis. Int J Oncol. 2006; 28:1571-5.

30. Liu YC, Gau JP, Yu YB, Hong YC, Yen CC, Liu CY, et al. Prognostic factors and treatment efficacy in patients with primary diffuse large B-cell lymphoma of the bone: single institute experience over 11 years. Intern Med. 2014;53:95-101.

31. Sanchez LA, Redondo AM, Munez OB, Sebastian E, Alcoceba M, Gonzalez M, et al. Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities? Ann Hematol. 2015;94:609-16.

32. Chi HS, Lee KW, Chiang FY, Tai CF, Wang LF, Yang SF, et al. Head and neck extranodal lymphoma in a single institute: a 17-year retrospective analysis. Kaohsiung J Med Sci. 2012;28:435-41.

33. Hart S, Horsman JM, Radstone CR, Hancock H, Goepel JR, Hancock BW, et al. Localised extranodal lymphoma of the head and neck: the Sheffield lymphoma group experience (1971-2000). Clin Oncol (R Coll Radiol). 2004;16:186-92.

34. Murawski N, Held G, Ziepert M, Kempf B, Viardot A, Hanel M, et al. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. Blood. 2014;124:720-8.

35. Suresh B, Asati V, Lakshmaiah KC, Babu G, Lokanatha D, Jacob LA, et al. Primary gastrointestinal diffuse large B-cell lymphoma: a prospective study from South India. South Asian J Cancer. 2019;8:57-9.

36. Yildirim N, Turkeli M, Akdemir MN, Simsek M, Tekin SB. Evaluation of 22 primary gastrointestinal lymphoma patients. Eurasian J Med. 2019;51:53-6.

37. Pandey M, Swain J, Iyer HM, Shukla M. Primary lymphoma of the colon: report of two cases and review of literature. World J Surg Oncol. 2019;17:18.

38. Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123:486-93.

39. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated nonhodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122:3251-62.